Method for preparation of peptides with psWang linker
AssigneePolypeptide Laboratories Holding (PPL) AB
InventorsLuciano Forni, Daniel Carbajo Lopez, Fernando Albericio Palomera
Life of this patent
Estimating the term…
Abstract
The invention discloses a method for the preparation of a peptide by liquid phase coupling of two fragments, an N-terminal fragment and a C-terminal fragment of the desired peptide, wherein the C-terminal fragment is protected on its C-terminal COOH by a psWang linker; the method is demonstrated with liraglutide wherein the C-terminal fragment carries the Palmitoyl-Glu-OtBu residue on the Lys.
Claims21
A method for the preparation of a peptide (PEP) which comprises a coupling in liquid phase of two peptide fragments, an N-terminal fragment (FRAG1) of peptide (PEP) and a C-terminal fragment (FRAG2) of peptide (PEP);
- wherein the C-terminal COOH of the C-terminal fragment (FRAG2) is protected by a psWang residue;
- the psWang residue is a residue of formula (psWang);
- wherein (*) denotes the covalent bond to the C atom of the CO residue of the C-terminal COOH of the C-terminal fragment (FRAG2);
- R1, R2, R3 and R4 are identical or different and independently from each other selected from the group consisting of H, C1-4 alkyl, C1-4 alkoxy, CN, F, Cl and Br;
- R5 and R6 are identical or different and are, independent from each other, H or C1-4 alkyl;
- m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
- wherein the C-terminal fragment (FRAG2) is prepared by a solid phase peptide synthesis (SPPS);
- wherein the psWang linker or the psWang residue respectively is connected to a first resin used for the solid phase peptide synthesis (SPPS) by an ether bond (ETHBOND2);
- wherein the ether bond (ETHBOND2) is cleavable under weakly acidic conditions using trifluoroacetic acid (TFA), trifluoroethanol (TFE), or hexafluoroisopropanol (HFIP);
- and
- wherein the first resin is selected from the group consisting of a chlorotritykhloride
- (CTC) resin, a Rink acid resin a SASRIN resin
- a resin modified with 5-(4-hydroxymethyl-3,5-dimethoxyphenoxy)valeric acid (HAL), and a resin modified with 4-(4-hydroxymethyl-3-methoxyphenoxy)butyric acid (HMPB);
- wherein the Rink acid resin, the SASRIN resin, the resin modified with HAL, and the resin modified with HMPB are used in the chlorinated form.
Dependencies are inferred from the claim text.